Together, let’s help more patients stay on therapy
Your partner in the journey to sleep and breathing health
Long-term adherence remains a major challenge in the management of obstructive sleep apnoea (OSA), chronic obstructive pulmonary disease (COPD) and obesity hypoventilation syndrome (OHS).
OSA
1 in 4 patients discontinue CPAP within the first year1
COPD
1 in 3 patients discontinue home NIV within the first year2 *
OHS
Up to 1 in 2 patients discontinue home NIV within the first year3 **
At ERS 2026, we explored three key areas where we can support you in improving therapy experience
Start therapy with confidence
Choose the right mask for your patients and establish an effective therapy experience from day one.
Focus where it matters
Use digital health solutions to support care by rapidly identifying issues needing priority intervention, and empowering patients to take an active role in their therapy.
Help patients stay engaged
Encourage patients to use self-management tools that provide them with education, motivation, and ongoing support.
Have a question?
Leave your details and one of our team members will be happy to get in touch.
Keep exploring
Get it right from the start
Mask choice is a key driver of therapy acceptance and adherence. As a clinician, you can help patients establish a positive therapy experience from day one.
Supporting long-term NIV success
Explore the latest evidence, from landmark clinical trials to real-world studies, to inform patient selection and treatment strategies and support long-term outcomes.
Support when you need it
From clinical education and product training to local field support, Resmed teams work alongside healthcare professionals to help support successful therapy management.
This content is intended for health professionals only.
PROMOTIONAL MATERIAL – CE-marked medical device (CE0123). Manufacturer: Resmed. Local contact: Resmed. Please refer to the instructions for use for relevant information related to any contraindications, warnings and precautions. This content doesn’t constitute medical advice, consult a qualified healthcare professional.
*more than half of these discontinuations were attributable to patient mortality ** depending on patient subgroup ***These testimonials are a genuine and documented account of the individual’s response to treatment. Outcomes and results may vary, and this individual’s response does not provide any indication, warranty or guarantee that other people will have the same or a similar experience. These presentations are based on the professional presenter experience, practice and on recent available relevant data which is not intended to be understood as state of the art. Dr Perger, Dr Frija, Prof. Crimi and Dr Patout were provided with a nominal financial incentive for providing the following testimonial.
References
- Pépin, J.-L.; Bailly, S.; Rinder, P.; Adler, D.; Szeftel, D.; Malhotra, A.; Cistulli, P.A.; Benjafield, A.; Lavergne, F.; Josseran, A.; et al. CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis. J. Clin. Med. 2021, 10, 936. https://doi.org/10.3390/jcm10050936
- Pépin JL, Herquelot E, Denis H on behalf of the medXcloud group, et alImpact of long-term non-invasive ventilation on severe exacerbations and survival in COPD: a French nationwide cohort study using multistate modelsThorax 2025;80:616-623.
- Bailly, S., Denis, H., Schmidt, A., Pépin, J.-L., Lavergne, F., Malhotra, A., Palot, A., Prigent, A., Benjafield, A., Herquelot, E., Cistulli, P., & Josseran, A. (2025). Health Trajectories around Noninvasive Ventilation Initiation for Obesity Hypoventilation Syndrome. Annals of the American Thoracic Society, 22(10), 1554–1566. https://doi.org/10.1513/AnnalsATS.202411-1160OC
Last updated: 09/2026